Hypofractionated Whole Breast Radiotherapy With Tumor Bed Boost for Early Breast Cancer or DCIS After Partial Mastectomy in Women Aged 20 to 85

What this Trial Is About

Researchers are studying hypofractionated breast radiotherapy with a simultaneous tumor bed boost in women who have early breast cancer or ductal carcinoma in situ after having partial mastectomy surgery. This observational study aims to evaluate this combined radiation approach using hybrid techniques to treat the whole breast and the tumor bed area, with the goal of monitoring tumor recurrence and side effects over time. The treatment involves hypofractionated radiation therapy delivered through advanced methods including field-in-field intensity-modulated radiation therapy FIF-IMRT to the whole breast and inverse-IMRT for the boost to the tumor bed. This radiation is given after breast-conserving surgery, focusing on improving targeting while limiting exposure to surrounding tissues. Participants will be monitored from enrollment through at least 2 years for tumor recurrence in the treated breast. Additional assessments include tracking early skin reactions up to 3 months after therapy, long-term breast fibrosis for up to 5 years, and quality of life measured with questionnaires at baseline and regularly until study completion. The study is sponsored by National Taiwan University Hospital and participation lasts up to 5 years with regular follow-up visits.

Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer